febit Expands its Leading Position in Next-Generation Sequencing
LEXINGTON, Mass. and HEIDELBERG, Germany, May 27 /PRNewswire/ -- febit today announced the receipt of US patent #7320862 on its microfluidic microarray-based method for extraction of DNA and RNA.
This method forms the basis of a novel technology that enables the expanded use of next-generation sequencers in genomic research. Further investigation of the human genome by resequencing will particularly benefit from the new method: febit uses its microfluidic biochip system for sequence-based selective isolation of nucleic acids from genomic samples. This new approach to high-throughput sequencing essentially relies on high-density microarray biochips with flexible design, a technology established by febit several years ago. The newly patented method is known as hybselect, targeted sequencing or sequence capture. Using this innovative technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample prior to sequencing.
febit microfluidic biochip systems have been successfully used for several years in DNA analysis and synthesis. The latest patent was now granted in the US, patents in Europe and other foreign countries will soon follow.
febit currently holds more than 20 patents and patent applications. In addition to bioanalytics, the company's intellectual property portfolio predominantly covers the production of synthetic genes on biochips, an area where febit holds several key patents. Using a focussed application strategy, febit has been able to secure intellectual property rights on important product components, processes and evolving technologies.
febit enables scientists to read, write and understand the code of
life: DNA. With its unique Geniom technology and services, febit is the
only company that puts the control of simplified genomic research in the
hand of the user. The seamless integration of DNA synthesis and analysis
and the superior support in experiment design and bioinformatics helps to
understand data and turn it into results. febit's team of experienced
scientists is dedicated to support customers to solve the challenge of
understanding biological processes. Geniom is a technological and service
platform successfully implemented in basic and applied research by renowned
institutions and companies. Geniom exploits cutting-edge microarray
technology for analysis and synthesis of genes and genomes, providing
superior time- and cost-efficiency combined with an unsurpassed spectrum of
febit holding gmbh Russo Partners, LLC
Eva Sterzel David Schull or Wendy Lau
Public Relations Manager +1-212-845-4271
+49 (6221) 6510-300 email@example.com
Copyright©2008 PR Newswire.
All rights reserved